SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: bob zagorin3/9/2011 3:16:57 PM
   of 1972
 
vicl rising on volume today. might be reaction to this..

Japan suspends use of some Pfizer, Sanofi vaccines
By Shawn Schroter

(Adds background on recall in second paragraph, comment from companies in sixth, seventh and eighth paragraphs.)

TOKYO (MarketWatch) -- Japan's health ministry said it has temporarily suspended the use of Prevnar, made by Pfizer Inc. as it investigates whether the deaths of four children are linked to the pediatric vaccines.

The children, whose ages range between six months and two years old, died after receiving either Prevnar, ActHIB or a combination of vaccinations, the ministry said in a statement. The deaths were reported between March 2-4.

Prevnar is a pneumococcal conjugate vaccine, while ActHIB is a type b haemophilus influenzae vaccine.

In 2009, Pfizer suspended distribution and quarantined a batch of Prevnar in the Netherlands following reports of the deaths of three infants around the time of vaccination.

The health ministry said that the suspension will be in place pending the results of an investigation made by a group of medical experts into the deaths that is expected to be released on March 8.

Pfizer "thoroughly evaluates all reported cases and works closely with health authorities to determine if there is any association with use of our medicines and vaccines," a Pfizer spokeswoman said Monday, noting that the health ministry has posed a number of questions to the drug maker and it is in the process of preparing responses to those inquiries.

She added that based on the company's evaluation, the Prevnar doses administered in the four cases were from three separate lots.

A spokesman for Sanofi said that his company is also awaiting the finding of the panel of experts and that it is not planning to recall ActHIB at this time.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext